Alkem Laboratories Ltd Q2 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ilf5bc1tl6sufeccuuz9j9ey.pdf

Key Takeaways


U.S. Business: Profitability Over Top Line

Vikas Gupta: "Rather than just chasing our top line, I think our focus largely on U.S. business has been on improving the profitability."

Domestic Formulation: Acute Drag, Chronic Pull

Vikas Gupta: "I guess there are more positives than concerns in our domestic business that we have. And that's why we are very bullish of our overall growth of 8% to 8.5% as far as the overall year is concerned."

Margin Walk & Levers


International & Emerging Bets


Capital Allocation & M&A

Nitin Agarwal: "Our cost of capital is around 12%, so -- and so definitely, we'll not go anything which is lower than the 14% to 15% of IRR."

Guidance & Commitments

CommitmentSpecificsTimeline
Domestic formulation growth8% to 9% for FY25; H2 better than H1, Q4 particularly strongFY25
Overall top line growthMid-single-digit for FY25FY25
EBITDA margin18.5% to 19% for FY25; improve by at least 100 bps annually thereafterFY25 and beyond
U.S. top lineFlattish to mid-single-digit erosion for FY25; H2 better than H1FY25
U.S. profitabilityContinue improving in H2; eventually converge toward overall company EBITDA marginH2 FY25 and over time
Enzene plant production startQ4 FY25 to Q1 FY26; break even in first yearQ4 FY25–Q1 FY26
MedTech product launchQ1 or Q2 of next financial yearQ1–Q2 FY26
Mirabegron U.S. launchBound by innovator settlement; launch only post-FY26Post-FY26
cGMP product with 180-day exclusivityLaunch expected in Q3Q3 FY25
Pre-operative expenses (MedTech + Enzene)At most ₹60–70 crores, flowing in Q3 and Q4Q3–Q4 FY25
Chronic business growthMuch higher than market growth, improving chronic share of portfolioNext 3 years
M&A IRR thresholdMinimum 14% to 15%Ongoing

Key Metrics

MetricQ2 FY25
Net profit₹688.6 cr, +11% YoY
EBITDA (H1 FY25)₹1,361.5 cr, margin of 21.1% vs 17.7% in H1 FY24
Revenue from operations (H1 FY25)+0.6% YoY growth
Full-year EBITDA margin guidance18.5% to 19%, improvement of ~100 bps YoY
Full-year revenue growth guidanceMid-single-digit growth
India business growth guidance8% to 9% for FY25
India business volume growth+1.1% vs IPM volume growth of 0%
India business IQVIA growth6.3%
PAN brand MAT growth12.8% vs market growth of 7.3%
U.S. business H1 performance15% degrowth, with 6% price erosion
U.S. business full-year outlookFlattish to mid-single-digit erosion
U.S. back orders2%, down from 38% at start of year
ROW markets growth (excl. U.S. and Chile)~30% in Q2
Chronic portfolio share of domestic business~20%
Trade generic share of domestic business~20%
Net cash~₹4,250 cr as of 30th September
Pre-operating expenses for MedTech and Enzene (full year)₹60–70 cr (revised from ~₹100 cr)
Enzene U.S. plant capex~₹450 cr
Biosimilars launched to market7 products
U.S. ANDA approvals145 products approved, ~100 in market
FY24 failure-to-supply penalties (U.S.)~₹140 cr